whatshot

RXDX   $199.92  0.10% Market Open

Prometheus Biosciences Inc
show_chart Advanced Chart of RXDX
Last Events:

2023-07-18 Trend pattern changed from расходящийся клин с наклоном вверх to восходящий треугольник.

2023-07-18 Signal in Stochastic changed from bullish weakening to bullish recovery. The stochastic indicator is in overbought territory and it heading north. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: main and signal line crossing.

2023-07-18 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in overbought territory and it heading north. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.

2023-07-18 Trend Power changed from slow to medium strength.

2023-07-18 Trend changed from linear up to flat and up.

2023-05-20 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in the upper part of the neutral territory and it falls. These factors indicate that the downside trend is confirmed. Last signal: main and signal line crossing.

2023-05-20 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.

2023-05-19 Trend pattern changed from расширяющаяся формация to расходящийся клин с наклоном вверх.

Current temperature: 0.23
ST: 0, Cor:

50-50 Year Forecast
Low with 50% probability: 115.59
Target: 190.00
High with 50% probability: 281.73
Analyst Recommendations:
Number of estimates 4
Target Price Mean 190.00
Mean unverified/preliminary 190.00 / 190.00
Target Price Low / High 160.00 / 200.00
Median / STD DEV 200.00 / 20.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Buy ActivelyBuy
rsi ActivelyBuy Buy ActivelyBuy
macd - - -
stoch ActivelyBuy - -
ma20 - ActivelyBuy ActivelyBuy
ma50 ActivelyBuy - -
ma100 Buy Buy -
Candlestick PatternJune 15, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US74349U1088
ceo Mr. Mark C. McKenna
Website https://www.prometheusbiosciences.com
Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.